Fish oil and arrhythmias
This article was originally published in The Tan Sheet
Executive Summary
"For individuals at high risk of fatal ventricular arrhythmias, regular daily ingestion of fish oil fatty acids may significantly reduce fatal ventricular arrhythmias," a study published in the Nov. 1 Circulation concludes. The randomized, double-blind trial followed 402 patients with implantable cardioverter/defibrillators who were at high risk for fatal ventricular arrhythmias for 12 months. Subjects were given either a 2.5 g EPA plus DHA pill daily or an olive oil control. The primary endpoint was time to first event for ventricular tachycardia or fibrillation, and events were confirmed by an electrophysiology lab at one of the 18 participating medical centers. Analysis showed "a trend toward longer time to first event in those randomized to the fish oil supplement," Alexander Leaf, MD, Massachusetts General Hospital, et al., state. "When probable events were added to the analysis, the risk reduction became significant," they add...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.